"MoMed Biotech"

A biotech company that drives innovative drug development by combining advanced artificial intelligence technology with research on the mechanisms of drug targets.

MoMed Biotech was established in April 2022 in Linping District, Hangzhou City. The company's founders are Professor Bai Chen from The Chinese University of Hong Kong, Shenzhen, and Professor Arieh Warshel, a Nobel laureate in Chemistry in 2013. MoMed Biotech's establishment has received strong support from the Linping District government and industrial capital, and it has completed tens of millions of yuan in angel round financing.

MoMed Biotech focuses on the earliest "drug discovery phase" of drug development. Driven by the research on the mechanisms of drug targets and combined with cutting-edge artificial intelligence technology, the company is engaged in the research and development of innovative small molecule drugs, biological macromolecules, and macromolecule-small molecule conjugate drugs. MoMed Biotech is committed to providing a more reliable new drug molecular design method, obtaining lead compounds with higher drug-likeness, improving the efficiency of new drug development, reducing research and development risks, shortening the R&D cycle, and saving industry costs.


MoMed Biotech has creatively proposed the incorporation of dynamic information related to the functional realization of target proteins into the design and development of AI models, and has developed a research and development platform for innovative drug design based on this concept.

This is the first time in the industry, and this research and development method has also been patented. The most crucial dynamic information is based on the computational biology theoretical system established by Professor  Arieh Warshel. Professor Warshel will also provide personal guidance to ensure the smooth progress of mechanism research and the rational effectiveness of data conclusions. Currently, MoMed is the only company in the world that can achieve this.

Based on MoMed Biotech's research and development platform, multiple R&D pipelines are currently in progress. The types of targets we have chosen are diverse and highly representative, including enzymes, ion channels, G-protein-coupled receptors, etc., which are involved in major diseases that threaten contemporary human health such as cancer, cardiovascular diseases, and diabetes. The most advanced pipeline has completed drug design and has entered the phase of molecular synthesis and preclinical biochemical experimental validation.

The biopharmaceutical industry has become a focus of competition in the new round of global development and holds significant strategic importance for national economic growth and the construction of a "Healthy China". For a long time, China's pharmaceutical industry has been in the stage of "following and imitating" foreign drugs, contributing relatively little to global new drug research and development. However, the development of computational biology and artificial intelligence technologies is triggering a "technological revolution" in the biopharmaceutical field. At a critical stage for China's pharmaceutical industry to shift from "following and imitating" to "original innovation," MoMed Biotech is determined to be the "vanguard" of China's innovative medicine, helping the nation to achieve a leapfrog advancement in this field.

Founding Team

Professor Bai Chen

The founder & CEO

The founder of MoMed Biotech( Hangzhou ) Biotechnology Co., Ltd. 

Professor Bai Chen obtained a bachelor 's degree and a master 's degree in Shanghai Jiaotong University. 

In 2017, he obtained a doctorate from Brandeis University in the United States. 

After graduation, Dr. Bai joined the research group of Professor Arieh Warshel, the 2013 Nobel Prize winner in Chemistry, as an assistant researcher. His research direction is multi-dimensional modeling and mechanism research on large-scale biomolecular machines. 

After returning to China in 2020, he joined The Chinese University of Hong Kong ( Shenzhen ), mainly engaged in the research and development of innovative small and macromolecular drugs driven by the mechanism of drug targets and combined with cutting-edge artificial intelligence technology.

In recent years, the main academic achievements : the first or corresponding author published in many academic journals, such as NATURE CHEMISTRY, JACS, PNAS, ACS CENTRAL SCIENCE, etc.


Young top talents of Pearl River in Guangdong Province

Outstanding Science and Technology Innovation Talent in "China High-Tech" by the Ministry of Science and Technology

Shenlong Talent in Longgang District, Shenzhen City

Peacock Plan Class C Talent in Shenzhen City

Professor
Arieh WARSHEL

Chief Scientist

Arieh Warshel was born in Kibbutz Sde-Nahum, Israel in 1940.He served in the Israeli army with the rank of Reserved Rank Captain from 1958 to 1962.Afterwards, he entered the Israel Institute of Technology in Haifa and obtained a bachelor 's degree in chemistry with the highest honor in 1966. 

After that, he entered the Weizmann Academy of Sciences in Israel and obtained a master 's degree and a doctorate in chemical physics in 1967 and 1969 respectively under the guidance of Shneior Lifson. After completing his Ph.D., he did post-doctoral work at Harvard University. From 1972 to 1976, he returned to the Weizmann Academy of Sciences as a senior researcher and associate professor.

The key computational program of molecular simulation he participated in has been widely used in different fields. Professor Warshel and his team pioneered the key methods to simulate the function of biomolecules, including the introduction of molecular dynamics in biology, the development of quantum mechanics and molecular mechanics pathways, the introduction of enzyme reaction simulation, the creation of microscopic simulation of electron and proton transfer processes in solutions and proteins, the creation of microscopic modeling of electrostatic interactions in macromolecules, and the introduction of protein folding simulation. He and his team recently elucidated the molecular origin of the vector action of molecular machines.

Winner of the 2013 Nobel Prize in Chemistry

Fellow of the National Academy of Sciences

Honorary Member of the Royal Society of Chemistry

Founder Award of Biophysics Society